
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3411975/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effects of preconception lifestyle intervention in infertile women with obesity: The FIT-PLESE randomized controlled trial. PLoS Medicine, 2022, 19, e1003883.	3.9	34
2	High-Sensitivity C-Reactive Protein (hS-CRP) levels and pregnancy outcomes in women with unexplained infertility after ovarian stimulation with intrauterine-insemination (OS-IUI) in a multi-center trial. F&S Reports, 2022, 3, 57-62.	0.4	2
3	Endometrial scratch to improve outcomes of expectant management in patients with unexplained infertility?. Fertility and Sterility, 2022, , .	0.5	0
4	A personalized medicine approach to ovulation induction/ovarian stimulation: development of a predictive model and online calculator from level-I evidence. Fertility and Sterility, 2022, 117, 408-418.	0.5	3
5	Biomarkers of Stress and Male Fertility. Reproductive Sciences, 2022, 29, 1262-1270.	1.1	1
6	Poor Reproducibility of Percentage of Normally Shaped Sperm Using WHO5 Strict Grading Criteria. F&S Reports, 2022, , .	0.4	2
7	Immediate weight loss before ovarian stimulation with intrauterine insemination is associated with a lower risk of preeclampsia in women with obesity and unexplained infertility. F&S Reports, 2022, , .	0.4	0
8	Endometrial thickness after ovarian stimulation with gonadotropin, clomiphene, or letrozole for unexplained infertility, and association with treatment outcomes. Fertility and Sterility, 2021, 115, 213-220.	0.5	21
9	Sleep Habits of Women With Infertility. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4414-e4426.	1.8	18
10	Relationship between semen regurgitation and pregnancy rates with intrauterine insemination. Fertility and Sterility, 2021, 116, 1526-1531.	0.5	2
11	The relationship of plasma antioxidant levels to semen parameters: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Journal of Assisted Reproduction and Genetics, 2021, 38, 3005-3013.	1.2	9
12	Effect of an Active vs Expectant Management Strategy on Successful Resolution of Pregnancy Among Patients With a Persisting Pregnancy of Unknown Location. JAMA - Journal of the American Medical Association, 2021, 326, 390.	3.8	15
13	Sperm deoxyribonucleic acid fragmentation: predictors, fertility outcomes, and assays among infertile males. F&S Reports, 2021, 2, 282-288.	0.4	1
14	Metabolic syndrome in obesity: treatment success and adverse pregnancy outcomes with ovulation induction in polycystic ovary syndrome. American Journal of Obstetrics and Gynecology, 2021, 225, 280.e1-280.e11.	0.7	14
15	Natural vs. programmed cycles for frozen embryo transfer: study protocol for an investigator-initiated, randomized, controlled, multicenter clinical trial. Trials, 2021, 22, 660.	0.7	4
16	Active vs Expectant Management of Persisting Pregnancy of Unknown Location—Reply. JAMA - Journal of the American Medical Association, 2021, 326, 2330.	3.8	0
17	Luteal-phase progesterone supplementation in non-IVF treatment: a survey of physicians providing infertility treatment. Human Fertility, 2020, 23, 239-245.	0.7	2
18	Human chromatin remodeler cofactor, RNA interactor, eraser and writer sperm RNAs responding to obesity. Epigenetics, 2020, 15, 32-46.	1.3	15

#	Article	IF	CITATIONS
19	Intrauterine insemination performance characteristics and post-processing total motile sperm count in relation to live birth for couples with unexplained infertility in a randomised, multicentre clinical trial. Human Reproduction, 2020, 35, 1296-1305.	0.4	17
20	Oil or water-based contrast for hysterosalpingography?. Fertility and Sterility, 2020, 114, 75-76.	0.5	2
21	Androgenicity and fertility treatment in women with unexplained infertility. Fertility and Sterility, 2020, 113, 636-641.	0.5	8
22	Metformin, rosiglitazone, or both for obese women with polycystic ovary syndrome?. Fertility and Sterility, 2020, 113, 87-88.	0.5	6
23	Gonadotropins with intrauterine insemination for unexplained infertility—time to stop?. Fertility and Sterility, 2020, 113, 333-334.	0.5	2
24	The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility, 2020, 113, 552-560.e3.	0.5	126
25	Families with children resulting from ART: psychosocial and financial implications. Human Reproduction Open, 2020, 2020, hoaa010.	2.3	2
26	OR11-04 Effect of Preconception Intensive vs. Standard Lifestyle Intervention on Birth Outcomes in Obese Women With Unexplained Infertility: A Multicenter Randomized Trial. Journal of the Endocrine Society, 2020, 4, .	0.1	0
27	Association between testosterone, semen parameters, and live birth in men with unexplained infertility in an intrauterine insemination population. Fertility and Sterility, 2019, 111, 1129-1134.	0.5	22
28	Lower prevalence of non–cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility. Fertility and Sterility, 2019, 111, 1011-1019.e1.	0.5	6
29	Do BRCA1 and BRCA2 gene mutation carriers have a reduced ovarian reserve? Protocol for a prospective observational study. BMJ Open, 2019, 9, e033810.	0.8	4
30	The efficiency of single institutional review board review in National Institute of Child Health and Human Development Cooperative Reproductive Medicine Network–initiated clinical trials. Clinical Trials, 2019, 16, 3-10.	0.7	13
31	Fertility Related Quality of Life, Gonadal Function and Erectile Dysfunction in Male Partners of Couples with Unexplained Infertility. Journal of Urology, 2019, 202, 379-384.	0.2	22
32	Associations between vitamin D levels and polycystic ovary syndrome phenotypes. Minerva Endocrinologica, 2019, 44, 176-184.	1.7	24
33	Comparison of sonohysterography to hysterosalpingogram for tubal patency assessment in a multicenter fertility treatment trial among women with polycystic ovary syndrome. Journal of Assisted Reproduction and Genetics, 2018, 35, 2173-2180.	1.2	5
34	Major depression, antidepressant use, and male and female fertility. Fertility and Sterility, 2018, 109, 879-887.	0.5	56
35	Midluteal Progesterone: A Marker of Treatment Outcomes in Couples With Unexplained Infertility. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2743-2751.	1.8	17
36	Racial and Ethnic Differences in Pregnancy Rates Following Intrauterine Insemination with a Focus on American Indians. Journal of Racial and Ethnic Health Disparities, 2018, 5, 1077-1083.	1.8	14

#	Article	IF	CITATIONS
37	Allostatic load, a measure of chronic physiological stress, is associated with pregnancy outcomes, but not fertility, among women with unexplained infertility. Human Reproduction, 2018, 33, 1757-1766.	0.4	28
38	Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype. American Journal of Obstetrics and Gynecology, 2017, 216, 493.e1-493.e13.	0.7	78
39	Association of uterine fibroids and pregnancy outcomes after ovarian stimulation–intrauterine insemination for unexplained infertility. Fertility and Sterility, 2017, 107, 756-762.e3.	0.5	26
40	Sexual function in infertile women with polycystic ovary syndrome and unexplained infertility. American Journal of Obstetrics and Gynecology, 2017, 217, 191.e1-191.e19.	0.7	23
41	Preconceptional antithyroid peroxidase antibodies, but not thyroid-stimulating hormone, are associated with decreased live birth rates in infertile women. Fertility and Sterility, 2017, 108, 843-850.	0.5	42
42	Time to "cool off� Examining indications for "elective deferred frozen embryo transfer― Journal of Assisted Reproduction and Genetics, 2016, 33, 1551-1552.	1.2	4
43	The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility. Fertility and Sterility, 2016, 106, 1600-1607.	0.5	7
44	Predictors of pregnancy and live-birth in couples with unexplained infertility after ovarian stimulation–intrauterine insemination. Fertility and Sterility, 2016, 105, 1575-1583.e2.	0.5	87
45	Lifestyle factors associated with histologically derived human ovarian non-growing follicle count in reproductive age women. Human Reproduction, 2016, 31, 150-157.	0.4	20
46	On-label and off-label drug use in the treatment of endometriosis. Fertility and Sterility, 2015, 103, 612-625.	0.5	38
47	Identification and replication of prediction models for ovulation, pregnancy and live birth in infertile women with polycystic ovary syndrome. Human Reproduction, 2015, 30, 2222-2233.	0.4	19
48	Assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial: baseline characteristics. Fertility and Sterility, 2015, 103, 962-973.e4.	0.5	36
49	Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. New England Journal of Medicine, 2015, 373, 1230-1240.	13.9	223
50	Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes. Fertility and Sterility, 2015, 104, 1522-1526.	0.5	34
51	Recruitment strategies in two reproductive medicine network infertility trials. Contemporary Clinical Trials, 2015, 45, 196-200.	0.8	8
52	Predictors of participant retention in infertility treatment trials. Fertility and Sterility, 2015, 104, 1236-1243.e2.	0.5	7
53	Validation of the power model of ovarian nongrowing follicle depletion associated with aging in women. Fertility and Sterility, 2014, 101, 851-856.	0.5	16
54	The Use of MRI in the Pre-surgical Evaluation of Patients with Androgen Insensitivity Syndrome. Journal of Pediatric and Adolescent Gynecology, 2014, 27, e17-e20.	0.3	14

#	Article	IF	CITATIONS
55	Predicting Reproductive Age with Biomarkers of Ovarian Reserve—How (and What) Are We Measuring?. Seminars in Reproductive Medicine, 2013, 31, 416-426.	0.5	13
56	Ovarian primordial and nongrowing follicle counts according to the Stages of Reproductive Aging Workshop (STRAW) staging system. Menopause, 2012, 19, 164-171.	0.8	32
57	Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertility and Sterility, 2011, 95, 170-175.	0.5	442
58	A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause. Human Reproduction, 2008, 23, 699-708.	0.4	445
59	Reproductive ageing and ovarian function: is the early follicular phase FSH rise necessary to maintain adequate secretory function in older ovulatory women?. Human Reproduction, 2005, 20, 89-95.	0.4	35